Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Last Updated: January 21, 2022

DrugPatentWatch Database Preview

Nextwave Company Profile

Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for NEXTWAVE, and what generic alternatives to NEXTWAVE drugs are available?

NEXTWAVE has two approved drugs.

There are fifteen US patents protecting NEXTWAVE drugs.

There are thirty-four patent family members on NEXTWAVE drugs in fourteen countries.

Summary for Nextwave

International Patents:	34
US Patents:	15
Tradenames:	2
Ingredients:	1
NDAs:	2

Drugs and US Patents for Nextwave

+ Get email alerts for changes to this table

Subscribe to access the full database, or Try it Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Nextwave Pharms	QUILLICHEW ER	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE, CHEWABLE;ORAL	207960-002	Dec 4, 2015		RX	Yes	No	11,103,495	⤷ Try it Free	Y			⤷ Try it Free
Nextwave Pharms	QUILLICHEW ER	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE, CHEWABLE;ORAL	207960-003	Dec 4, 2015		RX	Yes	Yes	9,844,544	⤷ Try it Free	Y			⤷ Try it Free
Nextwave Pharms	QUILLICHEW ER	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE, CHEWABLE;ORAL	207960-001	Dec 4, 2015		RX	Yes	No	10,857,143	⤷ Try it Free	Y			⤷ Try it Free
Nextwave Pharms	QUILLICHEW ER	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE, CHEWABLE;ORAL	207960-002	Dec 4, 2015		RX	Yes	No	11,103,494	⤷ Try it Free	Y			⤷ Try it Free
Nextwave Pharms	QUILLICHEW ER	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE, CHEWABLE;ORAL	207960-001	Dec 4, 2015		RX	Yes	No	11,103,495	⤷ Try it Free	Y			⤷ Try it Free
Nextwave Pharms	QUILLICHEW ER	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE, CHEWABLE;ORAL	207960-003	Dec 4, 2015		RX	Yes	Yes	10,857,143	⤷ Try it Free	Y			⤷ Try it Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Paragraph IV (Patent) Challenges for NEXTWAVE drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Extended-release Oral Suspension	5 mg/mL	➤ Subscribe	2013-08-02

International Patents for Nextwave Drugs

Subscribe to access the full database, or Try it Free
Country	Patent Number	Estimated Expiration
Spain	2721900	⤷ Try it Free
Israel	194042	⤷ Try it Free
Japan	2009530298	⤷ Try it Free
Israel	236847	⤷ Try it Free
Australia	2011359405	⤷ Try it Free
Australia	2013302657	⤷ Try it Free
>Country	>Patent Number	>Estimated Expiration

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck

Johnson and Johnson

Harvard Business School

Boehringer Ingelheim

Colorcon

McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.